carrie

Oncologist

[carrie @carrie29874598]

@whyeszhu 我刷手机容易晕

[carrie @carrie29874598]

@roxboxfix If the studies included in the meta-analysis predominantly favor combination therapy,the pooled results would be expected to favor the combination therapy as well.

[carrie @carrie29874598]

@hongjaechon @JHEP_Reports @StephenLChan1 @changhoon_yoo The number of patients with MVI is limited, and its adverse prognostic significance is already well established. However, these findings do not identify a preferred therapeutic strategy for this subgroup.

[carrie @carrie29874598]

@hongjaechon @JournalofNucMed Currently, patient selection for GPC3-targeted therapies (like ADCs, CAR-T, or antibodies) mainly relies on tissue IHC, but tissue acquisition can be difficult and fails to heterogeneity. Could immuno-PET become a standard tool for non-invasive stratification in the future?

[carrie @carrie29874598]

@ArndtVogel @LancetGastroHep @myESMO @EASLnews @ILCAnews high dose can lead to high toxicity, especially liver toxicity

[carrie @carrie29874598]

@whyeszhu 松弛感

[carrie @carrie29874598]

@drenriquegrande @OncoAlert @seom @CANVES_ES What is the contribution of Imjudo (tremelimumab)?

[carrie @carrie29874598]

@ArndtVogel @Annals_Oncology @myESMO @ASCO The 5yr OS of GC is worse than HCC though the ORR is better

[carrie @carrie29874598]

@whyeszhu 这个是1316+8068的复方，皮下制剂，也就是PD-L1+CTLA-4的复方

[carrie @carrie29874598]

@whyeszhu 要收钱？ 哪个软件要收钱？

[Faheem Ullah @Faheem_uh]

When you submit your paper to a journal

This is how reviewer 1 and reviewer 2 treat it

[carrie @carrie29874598]

@whyeszhu 老丈人喊你来喝酒的呀

[carrie @carrie29874598]

@whyeszhu 高估了自己，低估了京东，打脸来的如此之快😓

[carrie @carrie29874598]

@whyeszhu 这怎么搞，我完全不能碰这些~~以后妥妥的老年痴呆了

[carrie @carrie29874598]

@DrJenLi_Renal Is there a link to the full text please?

[carrie @carrie29874598]

@whyeszhu 男人都认为自己是全才，家里啥坏了都能修。比如室友修厨房下水道无数次了，每每看见他在那儿拔水管，我都是叹气+翻白眼的走开，控制住自己不要吐槽

[carrie @carrie29874598]

@DrAngelaLamarca Your presentation on ADAs was truly fascinated

[carrie @carrie29874598]

@tompowles1 @DrChoueiri Since the FDA has approved Merck's WELIREG® (belzutifan) for treating patients with advanced renal cell carcinoma (RCC) following prior treatment with a PD-1 or PD-L1 inhibitor and a VEGF-TKI, why is cabozantinib still used as the control arm in ph3 trial?

[carrie @carrie29874598]

so many choices in #HCC in Chinese Mainland~~~so many ICIs